A phase II dose-ranging study of histamine dihydrochloride (MAXAMINE®) and interferon-α-2b as a new therapy for chronic hepaitits C: 12-Week interim analysis
Y. Lurie, M. Beer-Gabel, S.D. Malnick, S. Hyle, K.R. GehlsenVolume:
32
Year:
2000
Language:
english
DOI:
10.1016/s0168-8278(00)80731-x
File:
PDF, 153 KB
english, 2000